Attenuation of Hypertriglyceridemia by apolipoprotein A4 via low-density lipoprotein receptor-related protein 1

This research project examines the mechanisms by which apolipoprotein A4 (apoA4) may attenuate hypertriglyceridemia through signaling involving the low-density lipoprotein receptor-related protein 1 (LRP1). Grounded in a research program that integrates lipid transport, neurophysiology, and metabolic regulation, this project situates apoA4 and LRP1 at the intersection of peripheral lipid handling and central nervous system control of energy and glucose homeostasis.

The work builds on previously documented expertise in apolipoproteins, lipid transport and lipoprotein synthesis and degradation, as well as focuses on gut peptides and hypothalamic neuropeptides that mediate gut-brain communication via the vagus nerve and sympathetic nervous system. Researchers aim to define how apoA4 interaction with LRP1 influences plasma triglyceride levels and to elucidate the downstream neural and metabolic pathways that translate receptor-ligand engagement into whole-body lipid and glucose regulatory outcomes. Methodologically, the study leverages a multidisciplinary toolkit consistent with Lo’s laboratory capabilities. Molecular and cellular biology approaches will be employed to characterize apoA4–LRP1 interactions and signaling cascades in relevant cell types, including hepatocytes and neurons. Chemical and chromatographic analyses will quantify lipoprotein classes and triglyceride-rich particles, while transmission electron microscopy can assess lipoprotein size and morphology when required.

Functional in vivo studies are anticipated in obese and diabetic animal models to evaluate physiological impacts on lipid and glucose metabolism. The project is poised to interrogate neural circuits directly: manipulations of vagal or sympathetic inputs will help determine whether neural pathways mediate apoA4–LRP1 effects on peripheral lipid metabolism. The project will also explore gut-derived signals—gut peptides and other mediators—that may coordinate with apoA4 to influence central neural circuits and peripheral lipid handling.

The significance of this work lies in bridging molecular receptor function with integrative physiology. Hypertriglyceridemia is a key risk factor for cardiovascular disease and is commonly comorbid with obesity and diabetes. By clarifying whether apoA4 acts through LRP1 to reduce circulating triglycerides and by delineating the neural and metabolic mechanisms involved, this research could identify novel targets for therapeutic modulation of dyslipidemia in metabolic disease contexts. Importantly, the emphasis on gut-brain-liver-adipose axes reflects a translational perspective: interventions informed by these mechanisms might leverage peripheral apolipoprotein biology, receptor signaling or neural circuit modulation to restore healthier lipid profiles.